Skip Navigation



Journal of the National Cancer Institute Advance Access published online on June 30, 2009
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djp201
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/16/1157    most recent
djp201v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Haddad, R. I.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haddad, R. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

CORRESPONDENCE

Re: Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation

Robert I. Haddad

Affiliations of author: Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA

Correspondence to: Robert I. Haddad, MD, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney St, Boston, MA 02115 (e-mail: robert_haddad@dfci.harvard.edu).

The first 10% of the full text of this article appears below.

Pointreau et al. (1) clearly showed that docetaxel, cisplatin, and 5-fluorouracil (TPF) is better than PF for larynx preservation in . . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?